These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 1711626)
1. The effect of the partial beta-1-adrenoceptor agonist xamoterol on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy. Thierfelder L; Holubarsch C; Hasenfuss G; Heiss HW; Just H J Cardiovasc Pharmacol; 1991 Apr; 17(4):593-9. PubMed ID: 1711626 [TBL] [Abstract][Full Text] [Related]
2. Effect of xamoterol on myocardial energetics in man. Sakai O; Fujita M; Sasayama S; Asanoi H; Nakajima H; Yokawa S Jpn Circ J; 1988 Feb; 52(2):149-54. PubMed ID: 2896256 [TBL] [Abstract][Full Text] [Related]
3. [Acute effect of the cardioselective beta-1-partial agonist, Corwin, on ventricular function and myocardial oxygen consumption in patients with dilated cardiomyopathy]. Amende I; Simon R; Hood WP; Lichtlen PR Z Kardiol; 1986 May; 75(5):291-5. PubMed ID: 2874668 [TBL] [Abstract][Full Text] [Related]
5. Myocardial energetics in patients with dilated cardiomyopathy. Influence of nitroprusside and enoximone. Hasenfuss G; Holubarsch C; Heiss HW; Meinertz T; Bonzel T; Wais U; Lehmann M; Just H Circulation; 1989 Jul; 80(1):51-64. PubMed ID: 2525432 [TBL] [Abstract][Full Text] [Related]
6. Influence of enoximone on myocardial energetics in patients with idiopathic dilated cardiomyopathy: comparison with nitroprusside. Hasenfuss G; Holubarsch C; Heiss HW; Meinertz T; Hofmann T; Just H J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S69-74. PubMed ID: 2480489 [TBL] [Abstract][Full Text] [Related]
7. Influence of the calcium-sensitizer UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy. Comparison with nitroprusside. Hasenfuss G; Holubarsch C; Heiss HW; Rattert B; Just H Basic Res Cardiol; 1989; 84 Suppl 1():225-33. PubMed ID: 2818456 [TBL] [Abstract][Full Text] [Related]
8. Influence of UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy. Hasenfuss G; Holubarsch C; Heiss HW; Just H Am Heart J; 1989 Sep; 118(3):512-9. PubMed ID: 2773772 [TBL] [Abstract][Full Text] [Related]
9. Acute and chronic effects of xamoterol in idiopathic dilated cardiomyopathy. Watanabe K; Hirokawa Y; Suzuki K; Shibata A Jpn Heart J; 1988 Sep; 29(5):603-15. PubMed ID: 2975712 [TBL] [Abstract][Full Text] [Related]
10. Acute hemodynamic and metabolic effects of ICI 118,587 (Corwin), a selective partial beta 1 agonist, in patients with dilated cardiomyopathy. Bhatia SJ; Swedberg K; Chatterjee K Am Heart J; 1986 Apr; 111(4):692-6. PubMed ID: 2869673 [TBL] [Abstract][Full Text] [Related]
11. Energetic consequences of substances currently used or recommended for long-term treatment of chronic heart failure. Holubarsch C; Hasenfuss G; Thierfelder L; Just H Basic Res Cardiol; 1991; 86 Suppl 1():107-12. PubMed ID: 1827977 [TBL] [Abstract][Full Text] [Related]
12. Left ventricular geometry, myocardial function and energetics of the dilated left ventricle. Influence of vasodilators and positive inotropic substances. Holubarsch C; Hasenfuss G; Thierfelder L; Just H Herz; 1991 Sep; 16 Spec No 1():298-303. PubMed ID: 1820296 [TBL] [Abstract][Full Text] [Related]
13. [Role of adrenergic beta receptor partial agonists in left ventricular failure of ischemic origin. Value of xamoterol (ICI 118,587, Corwin)]. Rousseau MF; Cheron P; Nannan M; Vincent MF; Lavenne F; Pouleur H Ann Med Interne (Paris); 1985; 136(3):247-50. PubMed ID: 2862823 [TBL] [Abstract][Full Text] [Related]
14. Effects of long-term xamoterol therapy on the left ventricular mechanical efficiency in patients with ischemic heart disease. Pouleur H; van Eyll C; Etienne J; van Mechelen H; Vuylsteke A; Rousseau MF Basic Res Cardiol; 1989; 84 Suppl 1():157-62. PubMed ID: 2573338 [TBL] [Abstract][Full Text] [Related]
15. Influence of phosphodiesterase inhibition on myocardial energetics in dilative cardiomyopathy. Hasenfuss G; Holubarsch C; Heiss WH; Bonzel T; Meinertz T; Just H Basic Res Cardiol; 1987; 82 Suppl 2():403-9. PubMed ID: 2959265 [TBL] [Abstract][Full Text] [Related]
16. Myocardial, coronary, and peripheral effects of xamoterol (ICI 118,587) in open-chest pigs. Galiè N; Metalli M; Zannoli R; Binetti G; Branzi A; Magnani B Cardiovasc Drugs Ther; 1989 Mar; 3(1):91-7. PubMed ID: 2577281 [TBL] [Abstract][Full Text] [Related]
17. Xamoterol in patients with dilated cardiomyopathy: an increase in beta-receptors in lymphocytes. Watanabe K; Hirokawa Y; Shibata A J Cardiol; 1988 Dec; 18(4):1015-25. PubMed ID: 2908309 [TBL] [Abstract][Full Text] [Related]
18. Long-term effects of xamoterol on left ventricular diastolic function and late remodeling: a study in patients with anterior myocardial infarction and single-vessel disease. Pouleur H; van Eyll C; Hanet C; Cheron P; Charlier AA; Rousseau MF Circulation; 1988 May; 77(5):1081-9. PubMed ID: 2896076 [TBL] [Abstract][Full Text] [Related]
19. Effects of the partial beta 1-adrenergic agonist, xamoterol, on hemodynamics and regional myocardial function during acute coronary occlusion in dogs. Miura T; Matsuzaki M; Toma Y; Yonezawa F; Kohno M; Katayama K; Ozaki M; Kumada T; Kusukawa R J Cardiovasc Pharmacol; 1990 Feb; 15(2):182-7. PubMed ID: 1689411 [TBL] [Abstract][Full Text] [Related]